Adlai Nortye Ltd. (ANL)
NASDAQ: ANL · Real-Time Price · USD
8.18
+0.28 (3.54%)
At close: Apr 2, 2026, 4:00 PM EDT
8.24
+0.06 (0.73%)
After-hours: Apr 2, 2026, 7:54 PM EDT
Adlai Nortye Employees
Adlai Nortye had 123 employees as of December 31, 2024. The number of employees decreased by 4 or -3.15% compared to the previous year.
Employees
123
Change (1Y)
-4
Growth (1Y)
-3.15%
Revenue / Employee
n/a
Profits / Employee
-$346,276
Market Cap
301.84M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 123 | -4 | -3.15% |
| Dec 31, 2023 | 127 | -2 | -1.55% |
| Jun 30, 2023 | 130 | - | - |
| Mar 31, 2023 | 129 | - | - |
| Dec 31, 2022 | 129 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| LENZ Therapeutics | 152 |
| Neurogene | 131 |
| Foghorn Therapeutics | 106 |
| Prelude Therapeutics | 79 |
| Surrozen | 41 |
| Inhibikase Therapeutics | 35 |
| Climb Bio | 29 |
| Opus Genetics | 28 |
ANL News
- 7 weeks ago - Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations - GlobeNewsWire
- 2 months ago - Adlai Nortye Announces $140.0 Million Private Placement Equity Financing - GlobeNewsWire
- 3 months ago - Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China - GlobeNewsWire
- 6 months ago - Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
- 2 years ago - Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024 - GlobeNewsWire
- 2 years ago - Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy - GlobeNewsWire
- 2 years ago - Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development - GlobeNewsWire
- 2 years ago - Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC - GlobeNewsWire